



Drug Quantity Management – Per Rx Telotristat ethyl tablets (Xermelo) Dispensing Limit

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	2
Background.....	2
References	2
Revision History	2

Product Identifier(s)

59069

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Xermelo 250 mg tablets

Maximum quantity per Rx = 90 tablets

The objective of this program is to manage potential dose escalation and to provide a sufficient quantity for covered indications.

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

All approvals are provided for 3 years in duration.

Xermelo 250 mg

1. Exceptions can be made when an individual has been on Xermelo 250 mg three time a day for at least 12 weeks and has not had an adequate improvement and a dose of up to 500 mg three times a day is needed according to the prescribing physician. Approve 180 tablets per dispensing.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (e.g., Somatuline® Depot [lanreotide for injection], Sandostatin® LAR Depot [octreotide for injection]) therapy in adults inadequately controlled by SSA therapy. The recommended dosage of Xermelo in adult patients is 250 mg three times daily taken with food. When short-acting octreotide is used in combination with Xermelo, administer short-acting octreotide at least 30 minutes after administering Xermelo.

References

1. Xermelo tablets [prescribing information]. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; March 2017.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	Reviewed by Clinical Specialists. No changes to criteria.	02/23/2020

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.